Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status approved
ATC Code L02BX03
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
TTD Drug ID D02STN
NDC Product Code 42291-024; 42291-073; 69238-1754; 60219-1754; 60687-455; 17337-0082; 54893-0070; 30007-838; 69238-1165; 60219-1165
UNII G819A456D0
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
SMILES CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.003570%
Exercise tolerance decreased08.01.03.0360.000734%Not Available
Malignant neoplasm progression16.16.01.0050.012446%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.001668%Not Available
Drug tolerance08.06.01.0030.000734%Not Available
Drug tolerance decreased08.06.01.0240.001135%Not Available
Musculoskeletal discomfort15.03.04.0010.000901%Not Available
Bone cancer metastatic16.29.02.001; 15.09.03.0040.000334%Not Available
Haemorrhage urinary tract20.02.03.005; 24.07.01.0070.002069%Not Available
Muscle mass15.05.03.0180.000734%Not Available
Cancer pain16.32.03.0040.000334%Not Available
Restless legs syndrome17.02.07.008; 15.05.03.0120.001635%Not Available
Angiopathy24.03.02.0070.000734%Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.0040.001001%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.004171%Not Available
Hot flush21.02.02.001; 08.01.03.027; 24.03.01.0050.077580%
Neurological symptom17.02.05.0100.000334%Not Available
Prostate cancer16.25.01.001; 21.04.02.0020.027528%Not Available
Adverse event08.06.01.0100.029764%Not Available
Cardiac disorder02.11.01.0030.010411%Not Available
Colon neoplasm16.13.02.001; 07.21.10.0010.000501%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Feeding disorder14.03.02.003; 19.09.01.003--Not Available
Embolism24.01.01.0090.000834%
Infarction24.04.02.0170.000834%Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Metastatic neoplasm16.16.01.0070.001001%Not Available
The 9th Page    First    Pre   9 10 11 12    Next   Last    Total 12 Pages